Figure 3.
Combined remdesivir and Lor. treatment dampens SARS-CoV-2 replication and inflammation
A: Illustration of mouse treatments. BALB/c mice were infected intranasally with SARS-CoV-2 501Y.V2 strain (7.1×104 CCID50). In some mice, Lor. (10 mg/kg) was administered (i.p.) 1 day before infection, then given each day over the course of infection; remdesivir (25 mg/kg) was administered (i.p.) at the time of infection and used once daily until euthanasia. Each treatment group contained five mice; three mice without infection or drug treatment were used as mock controls. Lungs were collected at 3 dpi. B: Body weight was monitored. Mice were euthanized and lung lobes were harvested for analysis. C: Viral replication was monitored by quantifying expression of nucleocapsid gene. D: mRNA levels of IL-6, TNF-α, CCL5, CXCL11, CCL20, and ICMA-1 were quantified using qRT-PCR and normalized to gapdh mRNA. E: Frozen lung sections were immunostained with VE-cadherin to indicate pulmonary microvascular integrity. Nucleus was stained with DAPI. Scale bar: 50 μm. Data are mean±SD. *: P<0.05;**: P<0.01;***: P<0.001.